Wednesday, October 05, 2022 · 2:00 – 3:00 pm EDT
Molecular Glues in Drug Discovery: Solutions that Stick for the Undruggable
Molecular glues have emerged as a promising approach for drug discovery to treat a wide range of diseases such as cancer, and inflammatory and immune diseases. Conventional small molecule inhibitors can only target a small portion of disease-causing proteins, leaving the majority as undruggable. However, protein degradation utilizing small molecule glues is able to recruit non-druggable proteins for rapid destruction.
Join Philip Chamberlain the Co-Founder, President, and CEO of Neomorph, Dr. Benjamin Ebert, the Chair of Medical Oncology of the Dana-Farber Cancer Institute, and Janet Sasso, Information Scientist at CAS as they discuss a landscape view of the research and drug discovery efforts for molecular glues, and applications in the treatment of diseases.